key: cord-1046203-p1totf3r
authors: Chauhan, Deepak S.; Prasad, Rajendra; Srivastava, Rohit; Jaggi, Meena; Chauhan, Subhash C.; Yallapu, Murali M.
title: Comprehensive Review on Current Interventions, Diagnostics, and Nanotechnology Perspectives against SARS-CoV-2
date: 2020-07-17
journal: Bioconjug Chem
DOI: 10.1021/acs.bioconjchem.0c00323
sha: 6af123755021d9f7bebc433e94a16a4711fec479
doc_id: 1046203
cord_uid: p1totf3r

[Image: see text] The coronavirus disease 2019 (COVID-19) has dramatically challenged the healthcare system of almost all countries. The authorities are struggling to minimize the mortality along with ameliorating the economic downturn. Unfortunately, until now, there has been no promising medicine or vaccine available. Herein, we deliver perspectives of nanotechnology for increasing the specificity and sensitivity of current interventional platforms toward the urgent need of quickly deployable solutions. This review summarizes the recent involvement of nanotechnology from the development of a biosensor to fabrication of a multifunctional nanohybrid system for respiratory and deadly viruses, along with the recent interventions and current understanding about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is popularly named as novel coronavirus 2019 disease (nCoV- 2019) . 1 The emergence of coronavirus disease 2019 is not the first pandemic due to coronaviruses. In the past decade, the outbreak of severe acute respiratory syndrome (SARS, 2002 and and Middle East respiratory syndrome (MERS, 2012) has shown the capability to cross the interspecies barrier and infect humans. Different from earlier coronavirus outbreaks, COVID-19 has spread to more than 200 countries with millions of cases and thousands of deaths, sparking international health organizations to declare a global health emergency. 2 It appears that the moderate mortality rate, high infection rate, and longer incubation period of SARS-CoV-2 are the perfect combination for prolonging the pandemic. This pandemic can induce a ripple effect and hard challenges to the global health system along with serious financial crises. In many countries, hospitals have been compromised with a shortage of doctors, nurses, and trained personnel due to crowding of COVD-19 patients. Almost all countries are facing the issue of shortage of personal protective equipment (PPE), ventilators, and other critical medical equipment.

Initially, a very low number of cases were reported due to lack of resources and inability to distinguish between common flu and COVID-19. For example, Indonesia has reported only 2 cases. 3 However, there is much tourism from China. Now, several nucleic acid and protein-based diagnostic tests are available for COVID-19. A few repurposed drug candidates are also under clinical trials, but none of them have shown good efficacy without major safety issues. 4, 5 Additionally, some of the vaccines have entered phase I, phase II, and even phase III clinical trials. 6 Apparently, the final approval may take more than 12 months; realizing the sense of urgency, interdisciplinary and deployable solutions are highly sought to control this pandemic.

Nanotechnology, an interest of chemistry, physics, biology, and medicine disciplines, emerged as a medically viable approach to enhance the efficacy of the system(s) with minimal efforts and resources. In general, nanotechnology-based interventions increase the specificity, selectivity, sensitivity, and multiplexing characteristics of the diagnostic tests. 7−9 In terms of therapeutic perspectives, nanotechnology can help to develop targeted delivery of therapeutics to avoid the severe systemic side-effects of the regimen. 10 The recent extensive exploration of the drug carriers toward enhancing their biocompatibility, biodegradability, and eco-friendly nature has opened the door of nanotechnology for a wide range of healthcare applications. Overall, nanotechnology advancements can be helpful not only to track COVID-19 but to offer innovative and affordable therapeutic solutions. Apart from therapeutic perspectives, there is a large scope of nanotechnology in early and accurate detection of COVID-19. In addition, nanotechnology can be applied for prevention purposes, which includes disinfecting surfaces to nanotextile coating for achieving improved viral inhibition or trapping. . SARS-CoV-2 genome organization, codified proteins, and binding of spike protein to ACE2 receptor. Inset: illustration of ACE2 interaction with the RBD of SARS-CoV-2. Abbreviation: S1, receptor binding subunit, S2. membrane fusion subunit; NTD, N-terminal domain; RBD, receptor binding domain; FP, fusion peptide; HR1, heptad repeat 1; HR2, heptad repeat 2; S1, receptor binding subunit; S2, membrane fusion subunit; TM, transmembrane anchor; IC, intracellular tail; NSP, nonstructural protein.

esophageal epithelial cells, enterocytes of the ileum and colon, and kidney tubules. Thus, the respiratory and digestive routes are the potential entry door for infection. 25, 26 A study revealed that spike proteins of SARS-CoV-2 bind to the ACE2 receptors of the airway passage cells, which cause the entry into the cells. 27 ACE2 is a homologue of ACE, an enzyme known for controlling hypertension. It is a transmembrane metallocarboxypeptidase (primary substrateangiotensin II) and key player in the renin−angiotensin system. Although the binding of SARS-CoV-2 to the ACE2 is not as strong as SARS-CoV, it is above the threshold and sufficient for infection. 28 Recent findings also suggest that some of the folds may bind tighter in comparison to SARS-CoV. 29 ACE2 facilitated entry of SARS-CoV-2 was examined systematically in the HeLa cells and Vero-E6 cells. 16, 25, 30 Further, it was noticed that the Gln493 residue of the SARS-CoV-2 receptor binding motif helps in maximizing the interaction with the ACE2. 31 The spike (S) protein is a homotrimer glycoprotein and composed of two subunits responsible for binding to host cell receptor, and fusion of virus and host cell membrane. 22, 31, 32 At the boundary of the cell membrane, the S protein is cleaved into the S1 and S2 subunits without breaking apart. The S1 subunit binds to the receptor while maintaining the prefusion conformation of the S2 subunit (containing the fusion machinery) for fusion with the host cell membrane. S protein priming is necessary for the fusion of SARS-CoV, i.e., breakage of S protein by cellular protease at the S 2 ′ sites. It leads to the activation of protein by rendering irreversible changes in the confirmation. The extensive decoration of S protein with Nlinked glycans helps in the proper folding and thus access to the host proteases ( Figure 2 ). For priming, Transmembrane Serine Protease 2 (TMPRSS2) is responsible. 30 Consequently, the Calu-2 human lung cell lines treated with the camostat mesylate (a serine protease inhibitor) efficiently blocked the partial infection of SARS-CoV-2.

The alveolar type I and II epithelial cells express the ACE2 receptor. 33 However, RNA profiling studies show that viral receptor ACE2 is concentrated in alveolar type II epithelial cells and express 20 other genes helpful in virus replication and transmission. It is important to note that ACE2 is expressed in only 0.64% of all human lung cells. The expression of ACE2 is correlated with the differentiation state of epithelial cells. 34 The fully differentiated cells (apical surfaces expressing more ACE2) are prone to viral infection, while poorly differentiated cells (express less ACE2) remain poorly infected. SARS-CoV-2 infection relates to the state of the cells, ACE2 expression, as well as ACE2 localization. The percentage of ACE2 positive cells is higher in Asians (2.5%) compared to Africans and Caucasians (0.47%). 35 Also, ACE2 expression is higher in males than females. 36 The lack of correlation between the mRNA expression and enzyme activity of ACE2 has been established using the drugs lisinopril and losartan. 37 Lisinopril treatment was found to increase the ACE2 mRNA level but not activity, while losartan treatment increased both the activity and the expression level of ACE2. Moreover, combination of losartan and lisinopril treatment has shown no increase in activity and offset in the level of ACE2 mRNA. This study suggests the involvement of angiotensin via ACE inhibitor or angiotensin II receptor antagonist (ARB) to regulate the ACE2 expression and activity. The correlation between hypertension drugs, ACE2 expression, and activity needs to be properly established for controlling the COVID-19. 

It is highly difficult to differentiate the COVID-19 using common clinical tests from other respiratory disorders (influenza, respiratory syncytial virus (RSV), human metapneumovirus, other coronaviruses, bacterial, mycoplasma, and chlamydia infections). 38 The patients' average age for COVID-19 infection is much higher than that of MERS and Swineorigin influenza A (H1N1). 39, 40 Most of the COVID-19 patients suffer from chronic comorbidities and undergo silent hypoxemia, i.e., no symptoms of respiratory failure. Some patients have failure of other vital organs, kidney, liver, and lungs, before respiratory failure. Thus, the new early warning score and quick sequential organ failure assessment may not help in foreseeing the respiratory failure. 41 3.1. Diagnosis. The impact of early detection offers prevention of potential cases, while delayed reporting leads to minimal control of contagious diseases. 42−44 Currently, there are a number of nucleic acid-and protein-based diagnostic tests available (Table 1) . However, there is also an urgent need for point of care (POC) devices for rapid, cost-effective, and selfdiagnosis.

3.1.1. Nucleic Acid-Based Diagnosis Tests. Nucleic acidbased diagnostic tests are the most common for SARS-CoV-2 detection. Isothermal techniques require no specialized equipment, like polymerase chain reaction (PCR). Reverse transcription loop-mediated isothermal amplification (LAMP) based tests use the strand displacement polymerase instead of heat to generate the single strand template. 45−47 It uses the 4−6 primers and DNA polymerase, which binds to different regions of the target genome, and the amplified DNA is detected by the change in turbidity, which can be reflected in the change in color due to change in pH or fluorescent dye incorporated double-stranded DNA. The reaction completes in less than 1 h at 60−65°C with ∼75 copies that can be easily detected. 48 This technique is very specific because of the usage of a high number of primers; it is simple, easy to visualize, has less noise, and does not require a thermocycler. 49 It can also be multiplexed at the reading or amplification stage by functionalizing the beads with different optical signatures or involvement of different genes to cut out the possibility of mutation leading to false negative tests. 44, 48 The multiplexing helps to increase the information, specificity, and sensitivity of the tests. However, the challenges of LAMP tests are optimization of conditions and primers.

The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based Specific High-sensitivity Enzymatic Reporter un-LOCKing (SHERLOCK) diagnostic technology test became famous during the Zika outbreak, and could also be used for SARS-CoV-2 detection. Herein, the cDNA is synthesized and amplified using isothermal reaction, and then it again converted to RNA. Cas13a binds to amplified RNA, and on specific target binding gets activated, which then cuts off the quencher from fluorescence to give the signals. 50, 51 It has been reported to detect ∼2000 copies/mL from serum and urine of Zika infected patients. 52 The optimized protocol for SARS-CoV-2 has been published with different Cas13a detection systems and soon might be commercialized. 53 3.1.2. Protein-Based Tests. For the protein-based tests, antigens and antibodies are used for diagnosis. However, changes in viral load during the course of infection cause difficulties in detection, e.g., a high viral load in the salivary gland during the first week of infection that later declines 54, 55 ( Figure 3) .

Antibodies may provide a longer window for detection; however, cross-reactivity of the antibody with other coronavirus antibodies poses a problem. 56 Currently, these serological tests 57 Rp3 nucleocapsid has been found to have 90% similarity with SARS related viruses. The serological tests are performed by adsorbing recombinant protein to the bottom of the multiwell plate, and then diluted patient serum is added to perform ELISA. The horseradish peroxidase functionalized secondary IgG anti-human antibody is added to obtain the signals. If anti-SARS-CoV-2 IgG is present, it will be sandwiched between the adsorbed protein and the anti-human IgG probe. Similarly, IgM has also been used for the sandwiched assay. It was found that after 5 days of symptoms, antibody level is increased. Like, on day 0 of SARS-CoV-2 infection, only 51% and 81% of patients were found positive for the IgM and IgG, respectively, and after 5 days, it increased to 81% and 100%, respectively. These antibodies may also be found in the suspected cases, as recent studies show other proteins and biomarkers may also be used for detection. 58 Currently, a number of serological tests have been approved by the FDA for the emergency use authorization (EUA) ( Table 1) . 3.1.3. Lymphopenia-Based Assessment. It has been observed that the course of the disease was different in different patients, but the variations in blood test parameters were constant from the onset of disease to death or discharge. The lymphocyte percentage was found to be the most consistent and significant parameter for the disease progress. 60 For example, in the sample size of 12 patients (death case) with the mean average age of 76, the lymphocyte percentage was reduced up to 5% in 2 weeks after the disease onset. In the case of 7 patients (average age 35, therapeutic time 35 days) with severe symptoms, the lymphocyte percentage decreased initially but increased to more than 10% when discharged; however, in 11 patients (average age 49, therapeutic window 26 days) with moderate symptoms, the lymphocyte percentage was almost constant and higher than 20% upon discharge. It shows lymphopenia to be one of the reliable parameters for determining the prognosis. The clinical data were collected from the General Hospital of Central Theater Command, Wuhan, China. 60 3.2. Current Treatment Options. 3.2.1. Repurposable Drugs. The repurposing of the drugs that have been approved for other indications has come up as an effective strategy to reduce the cost, time, and risk significantly in comparison to de novo drug development for COVID-19.

3.2.1.1. Chloroquine. Since 1934, the 9-aminoquinoline, known as chloroquine (CQ), has been an inexpensive and safe drug for the treatment of malaria and a prophylactic measure for autoimmune diseases. Recently, it has also been explored during in vitro studies for the antiviral properties against HCoV-OC43 and SARS-CoV. 61 It has been found to interfere with the ACE2 of the host cells and prevent the interaction of spike proteins of the SARS family of coronavirus. 62 However, the mechanism of action is still speculative. The determination of the precise mechanism is important for finding new prophylactic and therapeutic measures. The correlated studies show that chloroquine interferes with the pH-dependent viral fusion and replication, and also glycosylation of the receptor as well as envelope protein. 61, 63 Additionally, it also interrupts the assembly in the endoplasmic reticulum−Golgi intermediate compartment. Chloroquine also attenuates the expression of proinflammatory receptors and factors mainly responsible for the SARS-CoV-2-associated mortality. 61, 64 SARS-CoV-2, similar to synthetic nanoparticles, falls in the same range of shape and size. 65, 66 Thus, another mechanism is the suppression of phosphatidylinositol binding clathrin assembly protein (PICALM) for preventing the uptake of nanosized clathrin-mediated endocytosis 67−70 (Figure 4 ). This clathrin-mediated endocytosis path is being used by other members of the Coronaviridae family for entering the host cells.

In the case of SARS-CoV, it is known that after binding to ACE2, endocytosis-driven entry of the virus is triggered. 71 Moreover, chloroquine prevents the fusion of endosomes with the lysosome to disturb endocytic trafficking. 70 It disrupts the membrane recycling, and thus the entry of viruses. The pH change in endosome for the activation of endosomal protease like cathepsin required for priming of S protein can be disturbed due to chloroquine driven inhibition of endosomal acidification, which leads to stalling of the virus in the endosome. Thus, there are chances of multiple mechanisms of action that are reflected in the broad-spectrum nature of the drug. Hydroxychloroquine (HCQ)has been reported to have the same anti-SARS-CoV-2 activity along with a higher safety profile.

The FDA suggests that excessive and long-term usage of CQ and HCQ result in eye damage, corrected QT prolongation, neuropsychiatric effects, and hypoglycemia. 73 These risks are amplified several-fold when CQ and HCQ are combined with other drugs (e.g., azithromycin) reportedly prolonging the QT intervals. Furthermore, heart problems are amplified if the patient is also suffering from renal diseases. Also, a paper published in the reputed journal Lancet corroborated the ineffectiveness of CQ and HCQ either with or without the combination of macrolide in the treatment of COVID-19, and also concluded that it might cause ventricular arrhythmias in the hospitalized patients. All these were indicated to revoke the CQ and HCQ EUA. 74 This report also halted the enrollment of patients in the WHO Solidarity clinical trial arm and other random clinical trials in different countries. However, shortly after a few weeks, this paper was retracted due to conflict between the coauthors due to the veracity of data sources. Meanwhile, a study published in another reputed journal, New England Journal of Medicine, again established that CQ and HCQ are no better than a placebo in the treatment of COVID-19 hospitalized patients. However, no comments were made on the usage for pre-exposure prophylaxis, which salvaged the continuation of clinical trials in high-risk populations. 75 3.2.1.2. Ribavirin. Ribavirin (tribavirin) is an antiviral medication, a synthetic guanosine analog, widely used to treat hepatitis C, RSV infection, and viral hemorrhagic fever(s). It checks the hepatitis C virus polymerase and shows broadspectrum effects against other DNA and RNA viruses ( Figure  5 ). This drug was extensively used with or without steroids during the SARS outbreak. 76 The higher dose (1.2 to 1.4 g orally in every 8 h) for its effective action poses severe toxicities, e.g., hemolysis and liver injury. 77, 78 Its inhalation formulation has also shown no benefits over oral and intravenous administration. Clinical studies showed that ribavirin could work synergistically with interferon β and inhibits SARS-CoV replication. However, blood transfusion was required in 40% of the patients. 79 Ribavirin shows teratogenic (abnormalities of physiological development) activity, and is thus not recommended for pregnant women. 80 3.2.1.3. Lopinavir, Ritonavir, and Nelfinavir. Lopinavir (LPV) and ritonavir (RTV) are protease inhibitors widely used for the treatment of human immunodeficiency virus (HIV) ( Figure 5 ). RTV is combined with LPV to increase the half-life by inhibiting cytochrome P450. 81 The LPV/RTV has been combined with ribavirin, which has shown better outcomes in the treatment of SARS. 82 Combination therapy using a cocktail of interferon-β, LPV/RTV, and ribavirin has been employed for the treatment of MERS. 83 This combination therapy is effective within 7−10 days of infection. The known side-effects of this treatment include diarrhea, nausea, and hepatotoxicity. This treatment may pose exacerbated effects in the case of COVID- 19 patients (who may already be experiencing liver issues). It is important to note that HIV and SARS-CoV have different proteases; thus, there is also concern about the specificity of the combination. 70 Nelfinavir is a protease inhibitor of HIV, responsible for post-translational processing. 84 It strongly inhibits the replication of SARS-CoV, and is thus an option for SARS-CoV-2. 85 3.2.1.4. Remedesivir. Remedesivir (GS-5734) is a monophosphate prodrug of an adenosine nucleoside analog. Remedesivir has been reported to inhibit the human and zoonotic coronavirus, including SARS-CoV in in vitro and in vivo studies 86 ( Figure 5 ). This molecule shows superior activity (low EC 50 ) and selectivity of host polymerase against the Ebola virus. Remedesivir has been found effective in preventing lung hemorrhage during a murine MERS infection lung model. In the case of SAR-CoV-2, the in vitro studies have shown the EC 50 to 0.77 μM and EC 90 to 1.76 μM. 87, 88 In recent reports, the combination of remedesivir and interferon-β was found to have higher efficacy than the triple combination of LPV/RPV, ribavirin, and interferon-β. 105 In the United States, the first COVID-19 patient was treated with remedesivir when the patient's condition was critical. 89 The random and controlled clinical trials of remedesivir are in process, and results have started to come. Remedesivir has been approved by the FDA for emergency use after finding that it reduced the hospitalization stay of COVID-19 patients.

3.2.1.5. Umifenovir. Umifenovir (Arbidol, ABD) is a small indole derived molecule for the treatment of respiratory viral infections, influenza, and prophylaxis in Russia and China. 90, 91 The action mechanism includes interrupting the interaction of S protein and ACE2 receptor to inhibit the fusion of the virus to the host cell membrane 92 ( Figure 5 ). ABD shows broadspectrum antiviral activity by blocking the fusion of influenza A, B, and hepatitis C. The mesylate derivative of Arbidol has been found to be 5 times more effective than Arbidol in the treatment of SARS-CoV (in vitro). 93 A clinical trial data of 67 patients treated with Arbidol showed less mortality and a higher discharge rate compared to untreated patients. 94 However, further studies need to be conducted to reach any conclusion.

3.2.1.6. Nitric Oxide. Nitric oxide (NO) is a gas produced by NO synthetase and arginine. Nitric oxide changes to peroxynitrite by reacting with superoxides, and inhibits bactericidal and other cytotoxic reactions. 95 NO is given to manage the airway function and also used as an antiviral agent to inhibit the replication of RNA and protein synthesis of the virus. 96, 97 The S-nitroso-N-acetyl penicillamine (NO-donor) significantly blocks the replication of SARS-CoV in a concentration-dependent manner. 98 Thus, NO inhalation is being considered as another choice for the treatment of COVID-19.

3.2.1.7. Dexamethasone. Recently, it has been reported that corticosteroid dexamethasone reduces the mortality of COVID-19 patients by 30%. 99, 100 The higher mortality rate is primarily due to the hyperimmune response stemming from the inflammatory cytokine storm. Dexamethasone is an FDAapproved corticosteroid for immunosuppression, and 30 times more potent than cortisone. Although it inhibits the cytokine storm, also affects the T cells' adaptability and B cells' antibodyforming capability that could lead to persistently higher viral load even after the patient appears recovered. The function of macrophages required for blood clearance may be severely affected. Thus, it should be carefully used only for critically intubated patients and not for already recovering patients. It could be beneficial to give the combination of corticosteroid with natural flavonoids like luteolin known to have antiviral properties via nebulization for targeted delivery to the lungs.

3.2.2. Protease Inhibitors. 3-Chymotrypsin-like (3CL) protease, papain-like protease (PLP), and TMPRSS2 are the main proteases of coronavirus and responsible for the replication and inhibiting the host immune response. 101 Serine protease is mainly responsible for S priming and uptake of the virus. Thus, targeting of these proteases has been sought as a promising approach in controlling the coronavirus.

Camostat mesylate (CM), an inhibitor of TMPRSS2, can block the spread and pathogenesis of SARS-CoV and MERS-CoV ( Figure 5 ). It is natively used to treat chronic pancreatitis in Japan. It prevents the uptake of SARS-CoV-2 by the ACE2 receptor. Currently, CM is in phase 2 clinical trial in the US. Cinanserin is a serotonin receptor antagonist and a very old drug used to inhibit the 3CL protease and thus replication of SARS-CoV. 30 The SARS-CoV-2 is also found to produce 3CL protease; thus, cinanserin could be another choice in controlling the pandemic.

Flavonoids are natural antioxidants and have several other medicinal effects, including antiviral activity. Flavonoids from Pterogyne nitens inhibit the infection of hepatitis C. 102 The other flavonoids, such as herbacetin, pectolinarin, rhoifolin, and biflanoids, have been tested for the inhibition of 3CL protease. 103, 104 Quercetin 3-β-D-glucoside, herbacetin, and isobavachalcone have been found effective against the MERS-CoV. Diarylheptanoids (an extract from the bark of Alnus japonica) has been shown to inhibit the PLP of SARS-CoV very effectively. 105 Thus, the combination of cinanserin, flavonoids, and others could also be chosen as an alternative to fight against the SARS-CoV-2.

3.2.3. Biologics. The biologics have broadened the treatment options by leveraging the clinical practices during the SARS-CoV and MERS-CoV outbreaks. More than 500 patents have been filed featuring the antibodies, RNA, cytokines, vaccines, and other biologics. 106 3.2.3.1. Antibodies. The neutralizing antibodies are the most common biologics. The literature suggests that the S protein of SARS-CoV-2 has been the target for antibody development due to its role in the fusion and uptake of the virus into the host cells. 107 The site saturation mutagenesis, along with the human framework reassembly and DNA display technology, is being used to determine the complementary regions of potent humanized mouse antibodies with high affinities. The antibody (2978/10) with more than 80% neutrality has been selected, which specifically targets the fusion region of the S protein. Therefore, understanding the additional details about this region is critical for the development of efficient antibodies. 108 3.2.3.2. Cytokines. Low-molecular-weight biologics with immune-modulating properties can be generated to attack pathogens. 106 For ∼40 years, different types of cytokines (chemokines, interleukins, interferons, and lymphokines) have been recognized. Interferons are the most common ones used to regulate the viral load by restricting replication. Interferon α and β have been studied for the coronaviruses, and interferon β has also shown a positive effect against MERS-CoV. 109 The combination with LPV/RTV and ribavirin can be expected to restrict the SARS-CoV-2 growth.

3.2.3.3. RNA Therapy. Complementary RNA neutralizes the mRNA and stops its expression. The interfering RNA is 21−25nucleotides-long small interfering (siRNA) or micro RNA. The short hairpin RNA (shRNA) can be the precursors of siRNA, which folds into the hairpin structure and blocks the target gene. The antisense RNA is single-stranded, 19−23 nucleotides long, and occurs naturally or is synthesized. The delivery of interfering RNA is usually performed using viruses, bacteria, or delivery vectors like plasmids, liposomes, etc. 110 Patent CN1648249 presents that dsRNA targets the M protein region of the mRNA from SARS-CoV. siRNA-M1 targets the 220−241 region of the M-mRNA, while siRNA-M2 targets the 460−480 region of the M-mRNA. The interference efficiency is more than 70%. The N and E region targeted siRNA can also inhibit the expression from GFP N and GFP E Table 2 ; https://clinicaltrials.gov, http://www. chictr.org.cn, Data accessed on May 18, 2020). Most of the vaccine development is in the USA (46%), while the rest are in China (18%), Asia (except China) and Australia (18%), and Europe (18%). 6 Vaccines are broadly classified into the following types: attenuated, vector-based, protein-based, mRNA based, and DNA based vaccines 112 ( Figure 6 ). Since the SARS-CoV-2 shares significant homology with SARS-CoV and MERS-CoV, analyzing the existing research could facilitate the development of vaccines for SARS-CoV-2. The safety of the vaccine is a very important factor along with its efficacy. 106 Almost half of the vaccine development was focused on the receptor-binding domain (RBD) of the S protein. It was found that there was a higher number of neutralizing bodies due to the recombinant S protein subunit with only 2-fold less than those produced by SARS-CoV. 113 Attenuated Virus: After deleting the virulence determinant by reverse engineering, attenuated virus still remains the most robust and viable option for increasing immunity and wide cross-protection. 114 There are approaches like restricting the virus replication in the upper respiratory tract only with limited copy numbers. For example, mutations (Y6398H) at the Orf1a/b polyprotein inactivate (reduce the replication rate) the mouse coronavirus. 106 However, in the face of the pandemic, the large-scale production of attenuated virus in biosafety level 3 is a challenging task.

DNA Vaccine: The SARS antigen-specific CD8+ T cell response can be achieved with the help of chimeric nucleic acid, i.e., endoplasmic reticulum chaperone (e.g., calreticulin) linked to the antigen polypeptide of SARS-CoV. 115 Gold nanoparticles or other delivery vectors can further improve the delivery and the generation of humoral and T cell response specific to the nucleocapsid of SARS-CoV. It was observed that the titer of SARS was significantly reduced in vaccinated animals. DNA coated gold nanoparticles inducted both the humoral and cellular immune response with the help of IgG, neutralizing antibodies, and increase in T cell response (CD3+ CD4+ and CD3+ CD8+) for the release of TNF-α, IFN-γ, and IL-2. 116 Inovio Pharmaceutical announced that the DNA vaccine (INO-4800) is ready for SARS-CoV-2 and human trials to be initiated soon. 117 Protein Vaccine: GlaxoSmithKline (GSK) is developing a protein-based vaccine with the help of S protein and oil-based adjuvant. The administration of soluble S protein (obtained from trimer-tag technology) along with GSK2 adjuvant produced high levels of neutralizing antibodies, and IgG2a and IgG2b antibody response in animal models. 118 Patent 20070003577 relates the usage of full-length recombinant trimeric spike protein of SARS-CoV for the generation of TriSpike vaccine. It showed the native immunogenicity comparable to the convalescent plasma of SARS patients. Also, a hybrid vaccine based on MHC II by Antigen Express in collaboration with Chinese consortium, 119 which consists of (i) an invariant chain, i.e., peptide enhancing the antigen presentation, (ii) linker between the peptide and antigenic epitope, and (iii) an antigenic epitope for the MHC II molecule.

microRNA Vaccine: Moderna has filed a patent (WO2017070626) for the development of the mRNA vaccine by combining the multiple mRNAs of S, S1, and S2 proteins of SARS-CoV and MERS-CoV into lipid nanoparticle formulation. This combination shows a very high level of neutralizing antibodies in comparison to the mRNA encoded by the S2 subunit. The viral load was reduced by 90% and the generation of the high amount of neutralizing bodies after its administration in New Zealand white rabbits. Moderna has announced the mRNA-1273 vaccine for SARS-CoV-2 clinical trials. 120 Currently, it has successfully completed the phase I and II clinical trials and is now gearing up for phase III clinical trials. 121 The precision vaccines help in inducing the specific cytotoxic T-lymphocytes (CTLs) without generating the antibody response. 122 The clinical studies of SARS, MERS, and HIV have shown that the CTLs response protects patients from developing severe conditions due to a hyperimmune response. In the convalescent phase, the more severe the response, the higher the level of antibody was recorded in plasma. 123 Thus, the killing of infected cells with the help of CTLs in the absence of antibodies seems a better option. The CTLs induced by vaccines might kill the virus before it starts production. For example, CTLs should target the first polyprotein produced from the ORF lab of viral mRNA. The infected cell will process the polyprotein to peptides, and few of them will be presented on the surface of cells by the human leukocyte antigen (HLA) class I molecule, which could be recognized by CTLs. Hence, CTLs which are targeted to the replicase polyprotein will kill the infected cells even before it starts the synthesis of virus structural proteins. 124 It has been reported that CTLs can be induced with 80% probability by protein binding to more than 3 HLA class I molecule (Figure 7) .

Topical delivery of DNA using polyethyleneimine-mannose nanoparticles induces a potent CTLs response in mice, monkeys, and humans. 125, 126 Thus, a similar approach could be applied against SARS-CoV-2 by inhaling the particles and directing the CTLs in the lungs. 127 3.2.4. Plasma Therapy. Due to the lack of vaccines and drugs, convalescent therapy/immunoglobulin therapy remains a potential option for severely ill patients. 128 The serum of recovered patients is used to treat the infected patients, as it contains the specific antibodies against the pathogen, which may clear the free virus as well as infected cells. 129 Convalescent plasma therapy reduces the virus titer in the acute phase and expedites the recovery process with the potential for preventing the reinfection. 130 The viral load in the blood is at its peak on the first week of infection, and hence is ideal for receiving convalescent plasma. 131 The collection of plasma globulin from the recovered patients remains the most viable option in the fight against the SARS-CoV-2; however, safety issues need further consideration. This therapy is more effective than the hormonal shock therapy used during the SARS and H1N1 pandemic. 132 3.2.5. Nutritional Interventions. Vitamins also play a major role in the immune system. The deficiency of nutritional requirements is one of the reasons for the impaired immune response against infection. 133 For example, vitamin A plays a significant role in viral and bacterial infections. 134−136 Low vitamin A renders calves more susceptible for the bovine coronavirus. 137 Vitamin B functions as a coenzyme in many reactions. 138 Vitamin B and UV light have significantly reduced the titer dosage of MERS-CoV. 139 Additionally, vitamin B3 can also reduce the neutrophil infiltration to the lungs, and thus the inflammation. Vitamin C has also been reported to protect against coronavirus. 140 The chicken trachea organ culture demonstrates resistance to coronavirus after vitamin C supplement. It also helps in the production of histamines, which help in runny noses, sneezing, swollen nodes, and other flu-like symptoms. 141 Three clinical trials have shown the involvement of vitamin C in the prevention of pneumonia susceptibility. 142 Vitamin D is also presumed to have a significant role in COVID-19. Vitamin D deficiency makes calves prone to bovine coronavirus. 143 In addition to these vitamins, mucroporin-M1, emodin, promazine, and nicotinamide are also known to work against SARS-CoV and SARS-CoV-2.

There have been a number of nanotechnology inventions which were applied right from diagnosis, surgical and therapeutic interventions. Nanotechnology has emerged as a wonderful tool and technology to enhance the efficacy of existing therapeutic and imaging agents. A number of multifunctional nanoparticles have been developed and approved by the FDA for various indications, including cancer treatment. Bayer's aspirin is also a particle formulation for quick relief from pain. Now, there is a circumstance to tune already FDA-approved formulations for tackling COVID-19. This section delineates the nanotechnological advancements and resources that can be used for the diagnosis, prevention, and treatment of viral disease, and easily extrapolated for COVID-19.

Bioconjugate Chemistry pubs.acs.org/bc Review 4.1. Detection. Biosensors are an alternative to enzymelinked immunosorbent assay (ELISA) and have been developed for several viral diseases. 144 However, low sensitivity and specificity are a major concern. Nanotechnology plays an important role in biosensor(s) development. It facilitates the targeted sensing, multiple analyte detection, ability to mass transfer at short distances for fast response, etc. 8 This leads to high sensitivity, selectivity, and accelerated development of POC devices. Plasmonic nanoparticles, such as silver, gold, and other metal oxide nanoparticles, quantum dots, and graphene have gained significant interest in the field of biosensors ( Figure  8 ). 9, 145 The intriguing optical property (surface plasmon resonance) of nanoparticles is being utilized to enhance the electromagnetic radiative phenomenon (absorbance and scattering) in diagnosis. The localized surface plasmonic resonance (LSPR), surface-enhanced Raman spectroscopy (SERS), quenching, and fluorescence properties are widely used in biosensor function. Gold nanoparticles (AuNPs) attached to the antibodies, biomolecules, proteins, and aptamers can enhance the LSPR and SERS signals, and the energy transfer between the fluorophore and AuNPs. 9, 146 Currently, there are a number of nanomaterial-based biosensors available for the detection of SARS-CoV-2 and related viruses (Table 3) .

For example, AuNPs deposition on the indium tin oxide (ITO) coated glass slides was capable of enhancing the detection of electron transfer signals from the HIV-1 virus-like particles (VLP). 147 This system detects HIV-1 at a concentration of 600 ng mL −1 to 375 pg mL −1 . Silver nanoparticles (AgNPs) are useful in increasing the intensity of electron transfer to the electrode surface. AgNPs are mostly exploited in the electrochemiluminescence (ECL) biosensors. 145 Functionalization and immobilization of AgNPs provide enhancement to the ECL of the luminophores. Nanosilver substrate has been found very promising for the SERS, which helps in achieving reproducible signals in aqueous solutions. 148 Moreover, the combination of Ag and Au has been used for the synthesis of bimetallic NPs for more efficient sensing applications. 149 Silicon nanowires are emerging as an ultrasensitive and labelfree detection technique. Silicon nanowire-based transistors are able to detect even the single virus after modification with antibodies. 150 On combining the air sampling with the microfluidics, it was noticed to detect even airborne influenza-like H3N2 viruses. 151 A surface plasmon resonance biosensor (without label or enzyme amplification) can detect the HIV-related DNA with high accuracy and reproducibility at a linear range of 1 pM to 150 nM and limit of detection (LOD) of 48 fM. The time required for the test is ∼60 min. 152 Nanozymes are the artificial enzymes comprising nanomaterials that have similar efficiency and catalytic abilities as natural enzymes. 169 For example, Fe 3 O 4 nanoparticles exhibit intrinsic peroxidase activity, while many other nanomaterials have shown enzymatic activities such as catalase, oxidase, superoxide dismutase, and many others. 170, 171 Nanozymes can also regulate the redox level of the cells, as the excess ROS causes oxidative stress and damages the cells. 172 Nanozymes have been used for detecting viruses, such as HIV and Ebola. A BSA-Ag nanocluster formulation can enhance Hg 2+ oxidase activity, which can produce superoxide anions for the 3,3,5,5tetramethylbenzidine (TMB) oxidation. This system was able to detect the 20 nmol L −1 of HIV DNA. 173 Another nanozyme system was found to be 100-fold more sensitive and quick in the detection of Ebola. 174 Together, it is viable that by combining different types of antibodies and probes, these diagnostic strips can be applied for different viruses.

4.2. Nanotherapeutics. 4.2.1. Nanomedicine. The size and morphology of nanomaterials are comparable to the SARS-CoV-2, which can facilitate binding to the spike protein and help in the localized killing. There is an enormous demand for nanotherapeutics or nanomedicine (medicine in nanoparticles) Figure 9 . Anti-inflammatory action mechanism of curcumin. It follows diverse pathways to inhibit the inflammation. Abbreviation: Nuclear factor erythroid-derived 2(Nrf2), Kelch-like ECH-associated protein 1, antioxidant responsive element (ARE), glutathione S-transferase (GST), glutathione peroxidase (GSH), superoxide dismutase (SOD), peroxisome proliferator-acitvated receptor-γ (PPAR-γ), PPAR responsive elements (PPRE), nuclear factor-κB (NFκB), inhibitor of kinases (IκB Adapted with permission from ref 179. for the treatment of various diseases. These nanoparticles can efficiently deliver previously mentioned numbers of repurposing and other therapeutic agents. However, in this section, we focused on two molecules, curcumin and niclosamide: how nanoformulations of these molecules can be improved for viral diseases, including SARS-CoV.

Curcumin is a polyphenol compound obtained from Curcuma longa and extensively used as an anti-inflammatory agent. 175, 176 Thus, the usage of curcumin seems promising for the COVID-19 driven severe lung inflammation. Inflammation is the result of immune response, overexpressed inflammation markers, and increase in lipid peroxide and free radicals. 177 Curcumin efficiently interrupts various pathways, such as NF-κB, tumor necrosis factor-alpha (TNF-α), cyclin D1, signal transducer, cyclooxygenase, and transcription activators 178,179 ( Figure 9 ). It also suppresses the expression of interleukin 6 (IL-6) by inhibiting the mitogen-activated protein kinase (MAPK) and NF-kB signaling pathway. 180, 181 Curcumin inhibits the Epstein−Barr virus by blocking the inducers and suppresses the proliferation of Epstein−Barr virus transformed human B cells. 182 It can obstruct the integrase 1 for preventing HIV infection. 183 Curcumin has been found effective for the treatment of various viral diseases such as chikungunya, hepatitis C, Japanese encephalitis virus (JEV), vesicular stomatitis virus (VSV), flock house virus (FHV), herpes simplex virus (HSV), feline infectious peritonitis virus (FIPV), and RSV. 184, 185 It was observed that at 30 μM curcumin, the strains of HIN1, H6N1, and influenza A virus (PR8 strain) were inactivated, also the infection was reduced due to HSV-1 and HSV-2 virions in the Vero cells. 186 In addition, it has been tested in silico for the treatment of Ebola. 187 It also worked against the Zika virus in a dose-and time-dependent manner. 188 Although curcumin has diverse medicinal properties, the low bioavailability limits its application. Various methods have been proposed to increase bioavailability, such as loading curcumin in polymer micelles, polymer nanoparticles, liposomes, metal complexes, and analogs, as well as derivatives. 189 There are several nanoformulations of curcumin, with the most common o n e s b e i n g po l y ( l a c t i cc o -g l y c o l i c ) a c i d , p o l y -(butylcyanoacrylate), chitosan, solid lipid, and albumin nanoparticles. 190 For example, the binding of curcumin with chitosan increases its bioavailability, biodistribution, and chemical stability and reduce systemic toxicity. 191 Curcumin nanoformulations have been shown to have minimum inhibitory concentration of ∼1 mg/mL while the crude one had 350 mg/mL. 192 It reflects the superior anti-pathogenic activity of curcumin when encapsulated in nanoparticles. The PEGylated lipid formulations of curcumin have been found to be 10-fold more effective for malaria than crude curcumin. 193, 194 The composite nanofilms based on curcumin, chitosan, and silver nanoparticles or nanoclay have been reported to induce synergistic antibacterial effects. 195, 196 Niclosamide is an FDA-approved antihelmintic drug developed for the treatment of tapeworms and nematodes. Currently, WHO has listed it as one of the essential drugs. 197 Niclosamide inhibits oxidative phosphorylation and stimulates the ATPase activity in the mitochondria and regulate the other pathways, such as Wnt/β catenin, STAT3, Notch, mTORC1, NF-kB, NS2B-NS3, and pH in treatment of bacterial and viral infections, cancers, and other metabolic diseases. 198 Niclosamide inhibits the replication of SARS-CoV in less than 0.1 μM (EC 50 value) along with cutting off the cytopathic effect at 1 μM. 199 Its 2-chloro-4-nitroanilide derivative is a potent inhibitor of 3CL protease of SARS-CoV. Niclosamide was found to be more effective at a concentration of 10 μM to MERS-CoV with 1000-fold reduction in replication by inhibiting S-phase kinase associate protein 2 (SKP2) through autophagy induction. 200 This drug has also been tried for the treatment of flavivirus, hepatitis C, Ebola, rhinovirus, chikungunya, human adenovirus, and Epstein-Barr virus.

However, niclosamide is also not spared from demerits, such as non-negligible cytotoxicity, high hydrophobicity, low bioavailability, and absorption. To overcome these limitations, a number of strategies, such as chemical modification, prodrug, and loading in drug carriers, have been implemented to improve the pharmacokinetic properties and to maximize the therapeutic versus side-effect ratio. 201, 202 A nanocrystal suspension formulation of niclosamide (nebulizer, 1−5 μm droplet size) stabilized by the surfactant can deliver a therapeutic load to the lungs. 202 The pegylated nanoformulation has been proven to increase the hydrophilicity and half-life, enhance the bioavailability, and reduce the systemic toxicity. 203 Other methods are encapsulation inside albumin, solid lipid, and polymeric nanoparticles. In addition, it has been conjugated with the chimeric polypeptide, which self- assembles to form the monodisperse nanoparticles and worked as a prodrug for various types of infection. 204 4.2.2. Inorganic Nanoparticles. The commercial antiviral drugs for the influenza virus mainly target neuraminidase (NA) and matrix protein 2 (M2) ion channel. 205 The M2 ion inhibitor blocks the transportation of H + ions, thus the coating of the viral genome, and prevents the replication. NA inhibitors prevent the release of virus from the cells by interrupting the hydrolysis of the terminal sialic acid residues. The US Center for Disease Control (CDC) says that 99% of influenza virus strains show resistance to M2 inhibitors. 206 The continuous mutations have changed the drug binding sites of the influenza virus, and thus increased the infectivity and mortality rates. 207, 208 Another target is hemagglutinin (HA) (involved in the fusion of the virus with the host cells) of the influenza virus. 209 Silver nanoparticles interfere with the disulfide bonds of HA and block entry of the virus into host cells. 210 Additionally, there have been many combinations of silver and gold nanoparticles, such as tannic acid, chitosan, poly(Nvinylpyrrolidone) (PVP) and curcumin-modified silver, and gallic acid-modified gold nanoparticles for checking the infection of influenza virus. 211−215 Porous gold nanoparticles provide extensive surface area and more efficiently bind the disulfide bonds 216 and stop the viral infection compared to conventional inorganic nanoparticles ( Figure 10 ). 217 The other perspective is to develop the inanimate surface by spraying the antiviral nanoparticles. This will inactivate the virus even before it attacks the body. These nanoparticles can release active ingredients on the surface in a slow and controlled manner. Zinc oxide (ZnO), copper, silver, and other cationic nanomaterials are being used for the development of selfcleanable cloths with broad antiviral activity. 218, 219 There is a report that viral infections progress due to the deficiency of zinc; thus, being exposed to zinc due to nanocoating of inanimate surfaces might help another way. 220 There are established reports that SARS-CoV-2 spreads through the air in droplets, and it comes out when someone talks, sneezes, or even breathes heavily. In such conditions, the antiviral nanocoating on the mask can prevent such intermediate infection. Such coating approaches may desiccate the virions and reduce capillary condensation of water. 221 These nanocoatings can become active upon exhalation, i.e., in the presence of warm and moisturized air, but not in the cold and dried inhaled air. The implementation of nanocoatings can be widely applied without disrupting the supply chain of masks. 222 These coatings are already in use to prevent mold, mildew, and other humidity problems in buildings. 223 4.2.3. Multifunctional Nanotherapy. The long-life dosage regimen of antiretroviral therapy (ART) causes pill fatigue. Thus, there is a requirement of long-acting theranostic solutions. Nanomaterials act as contrast agents or contrast enhancers in imaging applications. Bismuth-and sulfurcontaining nanorods intrinsically radiolabeled with luteium 177 ( 177 LuBSNRs) can render both antiviral therapy and multimodal imaging. 224 The gold nanorods combined with the curcumin loaded poly (lactic-co-glycolic acid)-block-poly (ethylene glycol) (PLGA-b-PEG) copolymer are helpful for triggered and localized release of therapeutics along with photothermal capacity in one system. 225 The albumin-Bi 2 S 3 and magnetic nanoparticles can be developed for the combination of radiotherapy, magnetic hyperthermia, and chemotherapy. In comparison to nontargeted nanoparticles, the retention time of targeted nanoparticles increases by 3−6-fold. 226 Several other inorganic, organic, and hybrid multifunctional nanoparticles can be applied for viral diseases (Table 4 ).

The majority of the vaccines help in generating antibodies for neutralizing the pathogen; however, recent findings show that activation of both humoral and cellular immune response is necessary to control diseases like HIV, hepatitis C, and many others. 227−229 Virus-like nanoparticles (VLPs) balance the safety and immunogenicity of the vaccine. VLPs are noninfectious and at the same time carry similar protein compositions to that of the virus. Most of the VLPs do not have nucleic acid; some have but do not allow it to be replicated in mammals. Currently, hepatitis B and E and human papillomavirus vaccines are based on VLPs. 230 These vaccines require the adjuvants to be completely effective. The VLP size ranges 20−300 nm, which can be efficiently recognized by dendritic or other antigen-presenting cells. 231, 232 VLPs also help in generating the innate immune response with the help of pathogen-associated molecular patterns (PAMPs), leading to the generation of type I interferon (IFN-I), better cross-presentation capacity, and cell-mediated T lymphocyte response. 233−235 Further, VLPs have been studied to induce the cellular immune response, wherein antigen containing VLPs were presented by APCs to activate the pathogen-specific CD8+ T cells through a TAP- proteasome independent pathway. 236−238 VLPs are safer than conventional vaccines and can be injected into immunocompromised individuals. 239 There are a number of VLPs that have been developed for several viral infections ( Table 5 ). The Novovax patent (US20160206729A1) discloses that VLPs containing at least one trimer of S protein of MERS-CoV induced the high level of neutralizing antibodies in conjugation to proprietary adjuvant Matrix M in mice and cattle. These VLPs were proven to promote protection against the MERS-CoV. Recently, Novovax has announced that it is working with SARS-CoV-2 using patented recombinant technology and proprietary adjuvant. 4.2.5. Nanosponges. The nanosponge category of nanoparticles is a new generation of drug delivery system 249 and acts as virus filter(s). The unique structure and core of nanosponges can separate viruses. The exterior cross-connected structure with cavities (250−1 μm width) of nanosponge similar to RBCs can also release drugs at the site in a controlled manner. 250−253 Nanosponges can also act as depots for soaking up the toxins. For example, on the injection of nanosponges, bacteria and other pathogens attack to it, being similar to the RBCs. Once these depots are saturated with toxins, they go to the liver and filter out content. 253 Nanosponges have been used for the treatment of viral diseases like influenza, rhinovirus, RSV, HIV, and HSV. 254−256 Such systems with antivirals effectively inactivate and kill the viruses in nasal epithelial and lungs. 257 4.2.6. Autophagy Modulation. Autophagy has received significant attention in the past decade since the outbreak of SARS in 2002. There is evidence suggesting the involvement of endocytic pathways in facilitating the entry of coronaviruses like SARS-CoV and MERS-CoV via two critical steps, i.e., (i) clathrin-dependent endocytosis and (ii) cathepsin-mediated S protein cleavage. 258 It has also been experienced that enhancing the autophagy of viral proteins heightened adaptive immunity due to an increase in antigen priming. 259 In addition, the role of autophagy has been established substantially in the regulation of inflammatory cytokines. Thus, the autophagy modulating drugs in combination with antivirals might be another breakthrough in handling the COVID-19 crisis. Further, a recent study also suggests that out of two synonymous mutations in SARS-CoV-2, nonstructural protein 6 (NSP6) mutation could lead to a significant change in the pathogenicity and intracellular survival of the SARS-CoV-2 due to its involvement in the autophagic lysosomal machinery. 260 Thus, there is also a need to monitor this mutation and leverage the opportunity.

In addition, evidence shows that nanomaterials can be tuned accordingly to modulate the endocytic pathway toward the treatment and control of diseases like cancer and other neurodegenerative disorders, wherein the removal of protein aggregates and damaged cellular components is critical. 261 It is indicated that nanomaterials cause disturbances in the signaling pathways, lysosome destruction, oxidative stress, etc., which modulates the autophagy driven suicide of the cells. However, there are also reports wherein nanomaterials enhanced the survival of the cells. Further research is needed in this direction to discover the exact underlying mechanism to harness the potential of nanomaterials in autophagy modulation.

COVID-19 has caused havoc worldwide with trillions of dollars of losses and millions of deaths. There is an urgent need to find an effective solution to control the pandemic. This has boosted R worldwide and recent findings of high-resolution structure of 3CL protease and the 3D structure of the spike glycoprotein from SARS-CoV-2 have provided better understanding about the viral replication and pathogenesis, respectively. X-ray crystallographic studies of the spike protein reveal that it has some ridges which are more compact than the SARS-CoV, and responsible for adaptive and tighter binding to human ACE2 receptors. These advanced outcomes facilitate the development of vaccines and antivirals by correlating mutations. There are many reports wherein the therapeutic candidates show promising in vitro studies, while shows inefficacy or even cause fatal syndromes during in vivo studies and clinical trials. Consequently, more insights may be required for determining the effective binding pockets and finding efficient drug molecules. So, to be on the safer side, it is better to adopt broad-spectrum drugs and follow required precautions. It is also advised to look at the nanotechnological approaches for an improved theranostic deployable solution. In the past decades, there has been tremendous research on nanotechnology for increasing the efficacy of the therapeutics for various indications, which can be extended to COVID-19. 

-1273

Non-Replicating Viral Vector

Non-Replicating Viral Vector and Phase I/II

Immune Medical Institute, Lentiviral, and Phase I/II

BNT162 (a1, b1, b2, c2), (BioNTech, Fosun Pharma, Pfizer), RNA, and Phase I/II

Sinovac Biotech, Chemically Inactivated SARS-CoV-2, and Phase I/II

New COVID-19 vaccine, Beijing Institute of Biological Products, inactivated SARS-CoV-2, and Phase I

Live Attenuated Virus, and Phase I/II

2020) From SARS-CoV to Wuhan 2019-nCoV Outbreak: Similarity of Early Epidemic and Prediction of Future Trends

Coronavirus Outbreakan Evolving Global Health Emergency

Indonesia finally reports two coronavirus cases. Scientists worry it has many more

SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening

COVID-19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates

2020) The COVID-19 vaccine development landscape

Advances in the design of nanomaterial-based electrochemical affinity and enzymatic biosensors for metabolic biomarkers: A review

Preparation of Cuprous Oxide Mesoporous Spheres with Different Pore Sizes for Non-Enzymatic Glucose Detection

Application of Gold Nanoparticle to Plasmonic Biosensors

Latest developments in innovative manufacturing to combine nanotechnology with healthcare

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology

Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature

gclid= CjwKCAjwwYP2BRBGEiwAkoBpAu1yJ8Mb6TSqpia1mB9s9HtZ7 JOoHyfJeXtOqoICUILGJ7gBXsascRoCdYgQAvD_BwE

Clinical Characteristics of Coronavirus Disease 2019 in China

Gender Differences in Patients With COVID-19

Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

A new coronavirus associated with human respiratory disease in China

Cell entry mechanisms of SARS-CoV-2

Genomic variance of the 2019-nCoV coronavirus

The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells

The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv, 2020.01.30.927806. (27)

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

2020) Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Emerging Wu Han (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

14614−21. (35) The 1000 Genomes Project Consortium (2015) A global reference for human genetic variation

Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17beta-oestradiol-dependent and sex chromosome-independent

Critically ill patients with 2009 influenza A(H1N1) infection in Canada

Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection

Critical care crisis and some recommendations during the COVID-19 epidemic in China

An overview of disease surveillance and notification system in Nigeria and the roles of clinicians in disease outbreak prevention and control

The French human Salmonella surveillance system: evaluation of timeliness of laboratory reporting and factors associated with delays

Novel Coronavirus Disease (COVID-19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics

Rapid Detection of Novel Coronavirus (COVID-19) by Reverse Transcription-Loop-Mediated Isothermal Amplification

Rapid detection of COVID-19 coronavirus using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform

Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using Colorimetric LAMP

Detection of loop-mediated isothermal amplification reaction by turbidity derived from magnesium pyrophosphate formation

Loop-mediated isothermal amplification of DNA

SHERLOCK: nucleic acid detection with CRISPR nucleases

Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems

Nucleic acid detection with CRISPR-Cas13a/C2c2

A protocol for detection of COVID-19 using CRISPR diagnostics

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Journal of heart and lung transplantation: the official publication of the International Society for

Crossreactive antibody response between SARS-CoV-2 and SARS-CoV infections

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold-Immunochromatographic Assay Kit for Detection of Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia (COVID-19). medRxiv

A Peptide-based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Corona Virus Disease

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors

A Novel Coronavirus from Patients with Pneumonia in China

Clinical Cancer Nanomedicine

Liposomal chemotherapeutics

A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery

Antimalarials -are they effective and safe in rheumatic diseases

Insights from nanomedicine into chloroquine efficacy against COVID-19

Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems, US Food and Drug Administration

RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Managing SARS amidst uncertainty

Critics slam treatment for SARS as ineffective and perhaps dangerous

Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit

Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines

Hepatitis C in pregnancy: screening, treatment, and management

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Role of lopinavir/ ritonavir in the treatment of SARS: initial virological and clinical findings

Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome

Nelfinavir. A review of its therapeutic efficacy in HIV infection

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

Remdesivir as a possible therapeutic option for the COVID-19. Travel medicine and infectious disease 34

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

First Case of 2019 Novel Coronavirus in the United States

Arbidol as a broad-spectrum antiviral: an update

Arbidol: a broad-spectrum antiviral compound that blocks viral fusion

Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol

Clinical Features of 69 Cases with Coronavirus Disease

Nitric oxide

Nitric oxide and airway disease

An overview on severe acute respiratory syndrome (SARS)

Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus

Dexamethasone for COVID-19? Not so fast

The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds

Inhibition of SARS-CoV 3CL protease by flavonoids

Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus

The interferon system: an overview

Cross-Kingdom Small RNAs Among Animals

Inhibition of SARSassociated coronavirus infection and replication by RNA interference

The Race To Stop COVID-19

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity

Vaccines for Covid-19: Perspectives, Prospects, and Challenges Based on Candidate Sars, Mers, and Animal Coronavirus Vaccines

Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus

Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800

Clover and GSK announce research collaboration to evaluate coronavirus (COVID-19) vaccine candidate with pandemic adjuvant system

Generex Provides Coronavirus Update: Generex Receives Contract from Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines

Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study

Phase 3 COVID-19 Vaccine Trials Launching in July, Expert Says

2020) Features, Evaluation and Treatment Coronavirus (COVID-19)

T cell responses to whole SARS coronavirus in humans

Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial

Polyethyleniminemediated gene delivery to the lung and therapeutic applications. Drug Des

Nanotechnology approaches for inhalation treatment of lung diseases

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

Use of convalescent plasma therapy in SARS patients in Hong Kong

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

Selenoproteins and Viral Infection

Vitamin A and immunity to viral, bacterial and protozoan infections

Vitamin A supplements ameliorate the adverse effect of HIV-1, malaria, and diarrheal infections on child growth

Effects of dietary vitamin A content on antibody responses of feedlot calves inoculated intramuscularly with an inactivated bovine coronavirus vaccine

Riboflavin (vitamin B-2) and health

Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment

Vitamin C and SARS coronavirus

The effect of ascorbic acid on infection chick-embryo ciliated tracheal organ cultures by coronavirus

Vitamin C for preventing and treating pneumonia

Acute phase response elicited by experimental bovine diarrhea virus (BVDV) infection is associated with decreased vitamin D and E status of vitamin-replete preruminant calves

Advances in biosensing strategies for HIV-1 detection, diagnosis, and therapeutic monitoring

A label-free electrochemiluminescence immunosensor based on silver nanoparticle hybridized mesoporous carbon for the detection of Aflatoxin B1

Recent advances in designing nanomaterial based biointerfaces for electrochemical biosensing cardiovascular biomarkers

Highly sensitive localized surface plasmon resonance immunosensor for labelfree detection of HIV-1

Surface-enhanced Raman spectroscopy: A brief retrospective

Green synthesis and applications of Au-Ag bimetallic nanoparticles

Electrical detection of single viruses

Integrating silicon nanowire field effect transistor, microfluidics and air sampling techniques for real-time monitoring biological aerosols

Highly sensitive surface plasmon resonance biosensor for the detection of HIV-related DNA based on dynamic and structural DNA nanodevices

Piezoelectric immunosensor for SARS-associated coronavirus in sputum

-optic biosensor

Quantitative and sensitive detection of SARS coronavirus nucleocapsid protein using quantum dots-conjugated RNA aptamer on chip

2020) eCovSens-Ultrasensitive Novel In-House Built Printed Circuit Board Based Electrochemical Device for Rapid Detection of nCovid-19 antigen

Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor

Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection

An amplified electrochemical immunosensor based on in situ-produced 1-naphthol as electroactive substance and graphene oxide and Pt nanoparticles functionalized CeO2 nanocomposites as signal enhancer

Electrochemical Detection of the Oligomerization of PB1-F2 Influenza A Virus Protein in Infected Cells

A multi-virus detectable microfluidic electrochemical immunosensor for simultaneous detection of H1N1, H5N1, and H7N9 virus using ZnO nanorods for sensitivity enhancement

Silver nanoparticles coated graphene electrochemical sensor for the ultrasensitive analysis of avian influenza virus H7

Bifunctional magnetic nanobeads for sensitive detection of avian influenza A (H7N9) virus based on immunomagnetic separation and enzyme-induced metallization

Label-free Detection of Influenza Viruses using a Reduced Graphene Oxide-based Electrochemical Immunosensor Integrated with a Microfluidic Platform

Development of label-free optical diagnosis for sensitive detection of influenza virus with genetically engineered fusion protein

Nucleic acid sandwich hybridization assay with quantum dot-induced fluorescence resonance energy transfer for pathogen detection

Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes

Intrinsic peroxidase-like activity of ferromagnetic nanoparticles

Catalytic Mechanisms of Nanozymes and Their Applications in Biomedicine

Chemistry and biology of reactive oxygen species in signaling or stress responses

Label-free colorimetric sensor for mercury(II) and DNA on the basis of mercury(II) switched-on the oxidase-mimicking activity of silver nanoclusters

Nanozyme-strip for rapid local diagnosis of Ebola

Curcumin as a potential protective compound against cardiac diseases

Curcumin, inflammation, and chronic diseases: how are they linked?

The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update

Curcumin -A promising nutritional strategy for chronic kidney disease patients

Curcumin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-stimulated BV2 microglia

Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets

An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells

Inhibition of HIV-1 by curcumin A, a novel curcumin analog. Drug Des

Curcumin and Boswellia serrata gum resin extract inhibit chikungunya and vesicular stomatitis virus infections in vitro

A review on antibacterial, antiviral, and antifungal activity of curcumin

Turmeric: A Promising Spice for Phytochemical and Antimicrobial Activities

Curcumin and Natural Derivatives Inhibit Ebola Viral Proteins: An In silico

Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding

Curcumin nanoformulations: a future nanomedicine for cancer

Advanced drug delivery systems of curcumin for cancer chemoprevention

Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice

Antimicrobial efficacy of curcumin nanoparticles against Listeria monocytogenes is mediated by surface charge

Formulation of nanotized curcumin and demonstration of its antimalarial efficacy

Artemisinin and artemisinin plus curcumin liposomal formulations: enhanced antimalarial efficacy against Plasmodium berghei-infected mice

Nano cellulose dispersed chitosan film with Ag NPs/Curcumin: An in vivo study on Albino Rats for wound dressing

Green Synthesis and Characterization of Halloysite Nanoclay/ Curcumin/Ag Hybrid Nano Materials for Antibacterial Applications

Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential

Multi-targeted therapy of cancer by niclosamide: A new application for an old drug

Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus

SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection

Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities

Toward Repositioning Niclosamide for Antivirulence Therapy of Pseudomonas aeruginosa Lung Infections: Development of Inhalable Formulations through Nanosuspension Technology

Injectable pegylated niclosamide (polyethylene glycol-modified niclosamide) for cancer therapy

Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth

The impact of influenza epidemics on hospitalizations

Global epidemiology of influenza: past and present

Influenza virus resistance to neuraminidase inhibitors

A spring-loaded mechanism for the conformational change of influenza hemagglutinin

Interaction of silver nanoparticles with HIV-1

Tannic acid modified silver nanoparticles show antiviral activity in herpes simplex virus type 2 infection

Antiviral activity of silver nanoparticle/chitosan composites against H1N1 influenza A virus

Inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles

Inhibition of HIV fusion with multivalent gold nanoparticles

Porous gold nanoparticles for attenuating infectivity of influenza A virus

Virucidal Activity of Gold Nanoparticles Synthesized by Green Chemistry Using Garlic Extract

Inactivation of high and low pathogenic avian influenza virus H5 subtypes by copper ions incorporated in zeolite-textile materials

Metal nanoparticles: The protective nanoshield against virus infection

Here's how nanoparticles could help us get closer to a treatment for COVID-19

Superhydrophobic and superhydrophilic plant surfaces: an inspiration for biomimetic materials

Mass masking in the COVID-19 epidemic: people need guidance

UH Physicist's Nanotechnology Could Stop Coronavirus in its Tracks

Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues

Gold nanorods and curcumin-loaded nanomicelles for efficient in vivo photothermal therapy of Barrett's esophagus

Tumor Targeted Albumin Coated Bismuth Sulfide Nanoparticles (Bi2S3) as Radiosensitizers and Carriers of Curcumin for Enhanced Chemoradiation Therapy

Cytotoxic activities of CD8(+) T cells collaborate with macrophages to protect against blood-stage murine malaria

Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees

HIV control is mediated in part by CD8+ T-cell targeting of specific epitopes

Chinese biotech partnership brings first hepatitis E vaccine to the market

Sizedependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors

Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles

Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming

Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection

Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon

Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway

Cross-presentation of virus-like particles by skin-derived CD8(−) dendritic cells: a dispensable role for TAP

Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells

Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus

Safety and immunogenicity of a viruslike particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans

Comparative effectiveness of H7N9 vaccines in healthy individuals

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers

A plant-derived VLP influenza vaccine elicits a balanced immune response even in very old mice with co-morbidities

A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age

The application of nanosponges to cancer drug delivery

Nanosponge formulations as oxygen delivery systems

Cyclodextrinbased nanosponges as drug carriers

Nanosponge And Micro Sponges: A Novel Drug Delivery System

Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties

Investigation of Cyclodextrin-Based Nanosponges for Solubility and Bioavailability Enhancement of Rilpivirine

Nano based drug delivery systems: recent developments and future prospects

Diversity of betacyclodextrin-based nanosponges for transformation of actives

Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19

Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy

Targeting autophagy using metallic nanoparticles: a promising strategy for cancer treatment